Skip to main content

Table 6 Antiplatelet prescription in patients already using OAC classified by HAS-BLED score

From: Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry

 

Total patients

Non-antiplatelet HAS-BLED score

p

 

0–2

3 or more

All CAD, n (%)

408

353

55

 

 No antiplatelet

222 (54.4%)

196 (55.5%)

26 (47.3%)

0.253

 Single antiplatelet

153 (37.5%)

128 (36.3%)

25 (45.5%)

0.190

 Dual antiplatelets

33 (8.1%)

29 (8.2%)

4 (7.3%)

1.000

DES < 1 year, n (%)

27

23

4

 

 No antiplatelet

3 (11.1%)

3 (13.0%)

0 (0.0%)

1.000

 Single antiplatelet

7 (25.9%)

6 (26.1%)

1 (25.0%)

1.000

 Dual antiplatelets

17 (63.0%)

14 (60.9%)

3 (75.0%)

1.000

DES > 1 year or BMS for any duration, n (%)

125

108

17

 

 No antiplatelet

41 (32.8%)

35 (32.4%)

6 (35.3%)

0.814

 Single antiplatelet

73 (58.4%)

63 (58.3%)

10 (58.8%)

0.970

 Dual antiplatelets

11 (8.8%)

10 (9.3%)

1 (5.9%)

1.000

History of ACS within 1 year, n (%)

42

33

9

 

 No antiplatelet

21 (50.0%)

17 (51.5%)

4 (44.4%)

1.000

 Single antiplatelet

12 (28.6%)

9 (27.3%)

3 (33.3%)

0.699

 Dual antiplatelets

9 (21.4%)

7 (21.2%)

2 (22.2%)

1.000

CAD without prior ACS or PCI, n (%)

386

332

54

 

 No antiplatelet

 

189 (56.9%)

26 (48.1%)

0.102

 Single antiplatelet

 

115 (34.6%)

25 (46.3%)

0.053

 Dual antiplatelets

 

28 (8.4%)

3 (5.6%)

1.000

  1. A p-value < 0.05 indicates statistical significance
  2. OAC, oral anticoagulant; HAS-BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage; CAD, coronary artery disease; DES, drug-eluting stent; BMS, bare-metal stent; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention